Glaucoma, Vision & Longevity: Supplements & Science

VisualFieldTest.com

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

  1. The IOP Floor: How Episcleral Venous Pressure Limits Trabecular and Canal-Based Glaucoma Procedures

    3일 전

    The IOP Floor: How Episcleral Venous Pressure Limits Trabecular and Canal-Based Glaucoma Procedures

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/the-iop-floor-how-episcleral-venous-pressure-limits-trabecular-and-canal-based-glaucoma-procedures Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Understanding Eye Pressure and the “Floor” Set by Venous Pressure Glaucoma is caused by high pressure inside the eye (intraocular pressure, IOP). Most glaucoma surgeries work by opening new drainage routes for the fluid in the eye. Many modern procedures (known as minimally invasive glaucoma surgeries or MIGS) create openings in the natural drainage system, so fluid can exit through small veins on the surface of the eye (the episcleral veins). A key point is that these episcleral veins already have their own normal pressure – the episcleral venous pressure (EVP) – and you cannot drain eye fluid below that pressure. In other words, EVP sets a physiological floor for IOP. If the eye‐fluid pressure tries to go much below EVP, there is no pressure gradient to drive flow, so it “bottoms out.” Classic equations for eye fluid (Goldmann’s equation) even show that IOP equals the outflow pressure plus EVP (). In practice, this means no matter how much we open the drainage, the pressure cannot drop much below the level of the veins. Eveyscleral venous pressure is normally about 8–10 mmHg in a healthy eye (). So even a perfect trabecular bypass or canaloplasty can only lower IOP toward that range. How MIGS and Canal Surgeries Work Trabecular meshwork–based MIGS (like iStents, Trabectome, Kahook Dual Blade, GATT) and Schlemm’s canal surgeries (like canaloplasty or Hydrus stent) all aim to reduce resistance by removing or bypassing the trabecular meshwork and inner wall of Schlemm’s canal. Once those are opened, aqueous fluid flows through the normal canal and out through collector channels into the episcleral veins. In effect, these surgeries restore the natural pathway. Because the fluid still drains into the veins, the eye can only empty out until the pressure equalizes with the venous pressure. As one review explains, even a full 360° trabeculotomy can only lower IOP “to as low as episcleral venous pressure” (). In other words, if EVP is 9 mm, the IOP usually cannot go below about 9–10 mm from these procedures. Because of this limit, MIGS techniques are best for moderate IOP reduction. A recent evidence review noted that MIGS “typically cannot achieve extremely low IOPs since they do not bypass the episcleral venous pressure (EVP), usually ~8–10 mm Hg” (). In fact, most MIGS studies report IOP only dropping into the mid-teens (mmHg) range. For example, one long-term series found that Trabectome (an ab-interno trabeculotomy) reduced IOP by about 29% (e.g. 23→16.5 mmHg), whereas a trabeculectomy (a traditional bleb surgery) could reduce IOP by ~40–50% (e.g. 24→12 mmHg) in similar patients (). In plain language, MIGS could drop IOP from 23 to around 16–17 on average, whereas a filtering surgery often got pressures into the low teens. Patients and doctors should understand that this “floor” exists. If one needs very low IOP (for example in advanced disease where pressures in the single digits may be desired), simply opening the trabecular outflow may not suffice. By contrast, surgeries that divert fluid to low-pressure reservoirs (like a bleb) can go well below venous pressure, as we will explain below. Evidence from Clinical Studies Clinical studies of microinvasive surgeries support the idea that outflow is limited by downstream resistance. For instance, surgeons often look at the episcleral venous fluid wave (EVFW) during angle surgery: this is a sign of fluid flowing into the veins. If the wave is strong and widespread (meaning many collector channels are open and EVP is not obstructed), patients tend to achieve lower IOP after surgery. In one study of trabeculotomy (Trabectome), eyes with a clear, extensive EVFW (good flow) had a mean IOP of ~13.3 mmHg at 1 year, on only about 1–2 eye drops (). In contrast, eyes with little or no fluid wave (suggesting poor distal outflow) ended up at ~18.4 mmHg on nearly 3 medications (). In other words, when the path to the episcleral veins was effectively narrowed or pressured, the surgery did not lower pressure as much. Similar findings came from gonioscopy-assisted trabeculotomy (GATT): the greater the spread of the episcleral fluid wave during surgery (meaning more open veins), the lower the postoperative eye pressure and the fewer medications were needed (). These reports reinforce that if the eye’s veins or collecting channels are compromised or if EVP is high, simply unblocking the trabecular meshwork won’t achieve very low pressures. Conversely, high EVP can blunt the effect of trabecular surgeries. In practice, eyes with naturally high episcleral vein pressure (for example from vascular congestion or blood abnormalities) are known to respond poorly to MIGS. For example, eyes with conditions like Sturge–Weber syndrome, carotid-cavernous fistulas, or severe thyroid eye disease often have IOP at or above the level of their elevated EVP, and standard outflow surgery usually fails to drop it much further. While large trials on these exact patients are rare, the logic is clear: if EVP is already 15–20 mmHg in such cases, any surgery draining to those veins will likely leave IOP still high. Surgeries That Bypass the EVP Floor When the goal is to lower IOP below the episcleral venous pressure, surgeons turn to procedures that divert fluid away from the conventional venous route. The main options are trabeculectomy, tube shunts, and cyclodestructive treatments. Trabeculectomy (traditional filtration surgery) creates a new channel from inside the eye to a fluid reservoir (bleb) under the conjunctiva (the soft tissue covering the eye). Because the fluid drains into this bleb instead of the episcleral veins, the IOP is no longer tied to venous pressure. In fact, filtered fluid can be absorbed by the tissues or lymphatics at a pressure often well below normal EVP. Clinical studies show trabeculectomy commonly achieves very low pressures: mean postoperative IOP in one long-term study was only around 7–8 mmHg, and most patients easily achieved pressures ≤10 mmHg, on very few medications (). This is about 5–6 mm lower than typical glaucoma drains. In other words, trabeculectomy “bypasses” the EVP floor. Its power to lower IOP comes at the cost of more risks (like bleb leaks or hypotony), but it is the standard choice when very low IOP is needed. Tube shunts (glaucoma drainage devices) place a small tube from the eye to a plate implanted under the conjunctiva. The plate forms its own bleb-like space around it. Like trabeculectomy, the fluid leaves the eye to a tissue space rather than to the venous circulation. Over time, the new bleb capsule develops moderate resistance, but typically tubes achieve IOP around the low teens (often 11–12 mmHg in published comparisons) (). For example, a mixed study found tube patients averaged ~12 mmHg on medications at 5 years, compared to ~7–8 mm in trabeculectomy. Again, tubes are far less constrained by EVP than MIGS, though usually not quite as low as a perfect trabeculectomy. Cyclodestructive procedures (like cyclophotocoagulation) work differently: they reduce the eye’s fluid production by partially destroying the ciliary body (the tissue that makes fluid). These do not depend on outflow at all, so there is no venous pressure floor to consider. Cyclodestruction often achieves moderate drops in IOP (commonly into the mid-teens or lower) and can be repeated. It is generally used when other surgeries have failed or are unsuitable. Some newer MIGS-like options also bypass EVP indirectly. For example, the XEN and PreserFlo gel stents are tiny tubes placed into the eye that drain to a subconjunctival bleb (similar to a trabeculectomy). These work like “mini-trabeculectomies” and thus can achieve lower IOP than trabecular MIGS (). (They still depend on forming a bleb, so they carry some of the same healing issues as trabeculectomy.) Other experimental approaches, like suprachoroidal shunts, also avoid draining to the episcleral veins altogether. Choosing the Right Surgery When EVP is High So how should a patient and surgeon use this information? First, high EVP can often be suspected from clinical clues even if we do not measure it directly. Look for very red, dilated episcleral veins on eye exam, or “blood in Schlemm’s canal” seen on gonioscopy. Certain histories (like thyroid eye disease, Sturge–Weber, or neck vein obstruction) raise suspicion of high EVP. If a patient’s IOP seems out of proportion to their glaucoma severity or to their medications, consider whether elevated EVP could be a factor. If we suspect or know EVP is elevated, we should expect that MIGS or canaloplasty alone may not reach target IOP. These procedures are still valuable if only a modest drop is needed (for example, reducing IOP from 22 to 17 might be worth a MIGS in a mild case). But if the target IOP must be very low (say ≤12) or if the patient already has fairly high IOP despite maximum therapy, then a surgery that does not rely on episcleral outflow is likely a better choice. In practice this means: Severe glaucoma or very high IOP: Prefer trabeculectomy or tube shunt. These can reach lower pressures and can overcome even a high EVP. If a patient absolutely need Support the show

    13분
  2. Carotid-Cavernous Fistula and Glaucoma: Venous Hypertension at the Eye

    4일 전

    Carotid-Cavernous Fistula and Glaucoma: Venous Hypertension at the Eye

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/carotid-cavernous-fistula-and-glaucoma-venous-hypertension-at-the-eye Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Carotid-Cavernous Fistulas and Eye Pressure Carotid-cavernous fistulas (CCFs) are abnormal connections between an artery and the venous cavernous sinus at the base of the skull. In simple terms, blood that should flow through arteries is shunted directly into veins. This raises the blood pressure inside the eye’s venous system. The extra pressure backs up into the veins around the eye, raising the episcleral venous pressure (the pressure in veins near the surface of the eyeball). When this happens, the eye’s fluid outflow is blocked, and intraocular pressure (IOP) rises, potentially causing secondary glaucoma () (). Early signs of a CCF can include a red, swollen eye, a bulging eyeball (proptosis), a noise like a whoosh in the head (bruit), and vision changes. These findings result from venous hypertension – high pressure in the eye’s veins. Because of the slow, high-pressure blood flow, the normally thin conjunctival veins become “arterialized” (bright red and corkscrew-shaped). Patients may also have chemosis (conjunctival swelling) and double vision if eye-movement nerves are affected. Knowing these symptoms helps prompt imaging and treatment, which can quickly lower eye pressure and protect vision () (). How CCFs Raise Eye Pressure There are two main types of carotid-cavernous fistulas, and both create orbital venous hypertension. Direct CCFs (Barrow type A) occur when the main internal carotid artery tears directly into the cavernous sinus. This usually happens in trauma (head injury or skull fracture), or rarely from a ruptured aneurysm. Because the tear is large, these fistulas are high-flow. A huge wave of arterial blood rushes into the venous cavernous sinus and then retrogrades (flows backward) into the eye’s veins. Indirect or dural CCFs (types B, C, D) involve small meningeal branches of the carotid or external carotid arteries feeding the sinus. These connections are smaller and low-flow, often developing spontaneously in older adults. Even though dural CCFs are lower flow, they still raise sinus pressure over time () (). In both cases, the key is that arterial blood at high pressure enters the cavernous sinus, crowding out normal venous flow. This creates venous stasis and back-pressure. The superior ophthalmic vein (and sometimes inferior ophthalmic vein) carries blood from the eye to the cavernous sinus. When the cavernous sinus pressure climbs above the pressure in those veins, flow reverses or stalls (). These veins become engorged, and the normal balance of fluid in the eye is disturbed. The eye constantly produces watery fluid (aqueous humor), and normally this drains out through veins. If the veins are jammed by high pressure, the fluid cannot drain, and the eye pressure rises to match the venous pressure () (). The normal episcleral venous pressure is only about 8–10 mmHg (). In a CCF, that pressure can jump much higher. Once the episcleral pressure reaches the level of the IOP, any further increase in venous pressure forces the IOP to rise almost equally (). In practical terms, every extra mmHg of pressure in the eye’s veins directly adds to the eye’s internal pressure. As a result, patients with CCF often develop a secondary open-angle glaucoma where fluid cannot exit because of the high back-pressure () (). (Note: In rare cases, the raised pressure can also push the iris forward, shallowing the front chamber and causing angle-closure glaucoma, or cause poor retinal blood flow and new troublesome vessels. But most CCF-related glaucoma is from the simple effect of blocked venous outflow () ().) Recognizing the Key Eye Findings When a carotid-cavernous fistula develops, it often creates striking eye signs. One of the hallmarks is arterialized conjunctival vessels. Normally the white of the eye has fine red veins. In CCF, those veins look bright red, engorged, and tortuous (often described as “corkscrew” vessels) because they carry direct arterial blood () (). Patients usually have conjunctival chemosis – swelling of the clear membrane (conjunctiva) covering the white of the eye – causing a bloodshot, puffy appearance () (). Another classic feature is proptosis (bulging of the eyeball). Because the venous congestion extends behind the eye, the eye can protrude forward, and in a high-flow fistula it may even pulsate in time with the heartbeat () (). Eye movement can become limited too, and patients often develop double vision (diplopia) if the cranial nerves or engorged eye muscles are affected. There may also be ptosis (drooping eyelid) or an enlarged pupil on that side if the nerves in the sinus are involved. A very important clue is the orbital bruit. This is an abnormal whooshing or throbbing sound heard by placing a stethoscope over the eye or temple. High-flow fistulas typically create an audible bruit synchronous with the heartbeat; even low-flow fistulas can sometimes produce a subtle bruit, especially during Valsalva (holding breath or straining) () (). Finally, and often most importantly, the affected eye shows elevated intraocular pressure (IOP). As the episodes of venous hypertension progress, the IOP may climb significantly (we have seen cases over 30 mmHg) () (). Ophthalmologists will notice an engorged episcleral venous plexus on exam, often with blood visible in Schlemm’s canal (the eye’s drainage channel). A standard applanation tonometry test may even show “wobbly” blinking tonometer mires reflecting the pulsatility of the eye. In one report, more than 64% of patients with CCF had high IOP (22–55 mmHg) (). In short, a swollen, red, pulsating eye with corkscrew vessels and a bruit should immediately raise concern for a fistula () (). Imaging the Fistula and Eyes If a CCF is suspected from the eye exam, imaging is the next step. Several tests can pick up clues: CT or MR Angiography: These non-invasive scans of brain vessels can show an enlarged cavernous sinus, a dilated superior ophthalmic vein, or early filling of the venous system. They often suggest a fistula and can guide planning () (). Ultrasound with Doppler: A skilled sonographer can sometimes detect reversed blood flow in an orbital vein or a “color bruit” of turbulent flow. Eye ultrasound may show an enlarged or pulsating ophthalmic vein. Gadolinium-enhanced MRI/MRA: Can reveal enlargement and abnormal flow voids in the orbit and cavernous sinus. However, the gold standard for diagnosis and exact classification is digital subtraction catheter angiography (DSA) () (). This is an invasive X-ray test where contrast dye is injected into the carotid and other arteries under fluoroscopy. Angiography precisely shows the location, size, and type of fistula, and whether it is draining anteriorly to the eye or posteriorly to the brain. For example, angiography will diagnose a Barrow type A vs. D fistula and show if the superior ophthalmic vein is filling backward. It also allows measurement of flow. In practice, ophthalmologists often first order a CTA or MRA if suspicious, then confirm with angiography () (). Endovascular Treatment and IOP Effects Management of a CCF usually involves an interventional radiologist or neurosurgeon working with the eye doctor. The main goal is to occlude (block) the fistula, stopping the abnormal blood flow and restoring normal venous drainage. In direct (type A) fistulas, treatment is usually urgent. A catheter is threaded through the femoral or carotid artery to the cavernous sinus, and the connection is closed off with coils, balloons, or liquid embolic agents. Modern detachable balloons or platinum coils can seal the tear in the artery. Sometimes a stent or liquid glue (onyx) is used. Heidelberg et al. reported using a detachable balloon in a direct CCF (). In dural (indirect) fistulas (types B-D), the decision to treat depends on symptoms. Because these are low-flow, some will spontaneously close or remain asymptomatic. If eye pressure is high or vision is threatened, treatment is indicated () (). The embolization may go through arterial feeders or, more commonly, a transvenous approach via the venous system (through the inferior petrosal sinus or rarely via a cutdown on the superior ophthalmic vein). The goal is to deliver coils or liquid to the cavernous sinus to plug the fistula from the vein side. These endovascular procedures have become highly effective and relatively safe (). After the fistula is closed, venous pressure in the orbit drops and the eye congestion resolves. Notably, intraocular pressure often falls quickly. Case reports and series document dramatic IOP improvement after successful embolization () (). For instance, in one case, IOP in one eye dropped from 34 mmHg to 19 mmHg just one week after CCF closure (). Another study found that embolization lowered the patient’s IOP by about 9 mmHg on average (). In that report, after angiographic occlusion of a bilateral CCF, both eyes’ pressures fell from the mid-20s into the high teens (). This confirms that fixing the fistula is often the most powerful way to reduce eye pressure. Adjunct medical therapy for glaucoma is usually given until the fistula is closed. Patients may use combinations of eyedrops (beta-blockers, carbonic anhydra Support the show

    14분
  3. Glutathione-centered strategies: NAC vs GlyNAC vs dietary sulfur donors

    6월 23일

    Glutathione-centered strategies: NAC vs GlyNAC vs dietary sulfur donors

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/glutathione-centered-strategies-nac-vs-glynac-vs-dietary-sulfur-donors Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Glutathione and Eye Health Glutathione (GSH) is a small but mighty antioxidant produced by our cells. It acts like a detoxifying shield against damage from free radicals and high sugar levels. The eye, especially the retina, lens, and cornea, needs glutathione to stay healthy. In fact, diseases like glaucoma and retinal degeneration often show low glutathione levels, indicating oxidative injury (). For example, glaucoma patients have lower blood glutathione than normal, suggesting that boosting GSH could protect retinal cells and the optic nerve (). Similarly, wounds—including surgical incisions and diabetic skin wounds—heal more slowly when oxidative stress is high () (). In short, keeping glutathione high helps eyes resist stress and helps wounds heal well. Modern medicine explores ways to raise GSH inside cells. Three main strategies are used: taking N-acetylcysteine (NAC) supplements, taking NAC together with glycine (called “GlyNAC”), or eating foods rich in sulfur-containing amino acids (like cysteine and methionine). Each approach has different effects on eye tissues, surgery recovery, blood sugar, and digestive comfort. N-Acetylcysteine (NAC): A Glutathione Booster NAC is a modified form of the amino acid cysteine. When you take NAC, your body converts it into cysteine, which is one of the building blocks for making glutathione (). This makes NAC a powerful way to raise intracellular GSH. Typical oral doses are around 600–1200 mg per day (often split into two or three doses), but some studies have safely used up to 1800 mg two or three times daily (). Eye benefits. Ophthalmology studies have found promising effects of NAC for retinal diseases. In one trial of retinitis pigmentosa (an inherited retinal degeneration), patients took NAC (up to 1800 mg twice daily) for 6 months. Those taking NAC showed improved retinal light-sensing and visual function () (). This suggests NAC helped protect photoreceptors (cells that detect light in the retina) by raising antioxidants. NAC has also been tested for eye surface injuries: in experiments on corneal (front of the eye) healing, high blood sugar slowed wound closure, but adding NAC restored normal healing speed (). In other words, NAC counteracted the harmful effects of glucose on corneal cells. Wound healing. Outside the eye, NAC also helps general wound repair. Animal studies of diabetic wounds show that topical NAC (in a skin dressing) markedly sped up early wound closure, with more new tissue forming at the wound edges (). Reviews of many experiments report that NAC can improve skin wound healing (for example, by boosting new blood vessel growth and collagen formation) () (). Even complex surgical healing may benefit: chronic oxidative stress (low GSH) is known to impair post-operative recovery (), and antioxidants like NAC have been shown to reduce complications in surgical patients. Blood sugar (glycemic) effects. NAC can improve insulin sensitivity. In women with polycystic ovary syndrome (who often have high insulin and sugar levels), 1.8 g/day of NAC for 5–6 weeks significantly lowered insulin responses and improved insulin sensitivity (). NAC did not raise blood glucose, but it helped the body handle sugar better. In older people, combining NAC with glycine (see below) greatly reduced measures of insulin resistance and fasting insulin levels (). In practice, taking NAC is unlikely to cause low blood sugar problems; instead, it often slightly improves sugar metabolism. Tolerability. Most people tolerate NAC well, but digestive upset is the most common side effect. Nausea, vomiting, diarrhea or abdominal discomfort can occur, especially at higher doses (). In one ocular trial, about a third of patients had mild GI side effects on high-dose NAC (1800 mg three times daily) (). These usually improved if the dose was lowered. To minimize issues, NAC is best taken with food or in divided doses. NAC’s sulfur smell/taste may also be noticeable, but it is otherwise safe with few drug interactions (). GlyNAC (Glycine + NAC): Synergistic Precursor Pair GlyNAC refers to taking glycine together with NAC. Glutathione is built from three amino acids: glutamate, cysteine, and glycine. While NAC provides cysteine, your body also needs enough glycine to complete the process. Some research suggests glycine is often the second limiting factor for GSH production (). In other words, if glycine levels are low (as can happen in low-protein diets or aging), using NAC alone might not fully boost GSH. Human studies. A notable clinical trial in older adults tested GlyNAC supplementation (100 mg/kg of NAC plus 100 mg/kg of glycine daily, about 7 grams each for a 70-kg person) versus placebo. After 16 weeks GlyNAC doubled or tripled muscle glutathione levels and lowered markers of oxidative stress (like TBARS and F2-isoprostanes) to youthful levels () (). GlyNAC also improved insulin resistance (fasting insulin and HOMA-IR fell by ~64%) and reduced inflammation markers (CRP, TNF-α) (). Participants reported better energy and exercise capacity too. In short, GlyNAC safely and effectively reversed age-related glutathione deficiency and metabolic stress () (). These benefits would also help healing and perhaps protect nerves by reducing chronic inflammation. Glycine effects on blood sugar. Separate research shows glycine alone can blunt blood sugar spikes. In a classic study of healthy adults, 5 g of glycine given before a glucose drink halved the blood sugar rise, likely by triggering insulin or gut hormones (). So adding glycine enhances the positive metabolic effects of NAC. Importantly, GlyNAC together did not cause low blood sugar; it mostly improved insulin efficiency, meaning the same sugar load was handled with less insulin. Tolerability. Glycine is very gentle. Large doses (several grams) rarely cause side effects except occasional stomach upset or sleepiness (glycine is a calming amino acid). In the GlyNAC trial, the combination was well tolerated for 16 weeks, with no serious adverse events (). In fact, people often find taking glycine pleasant (it tastes slightly sweet) and it can even improve sleep. Thus, the GlyNAC approach tends to have fewer stomach issues compared to high-dose NAC alone. Dietary Sulfur-Donor Foods Besides supplements, your diet can supply sulfur amino acids and related nutrients to boost glutathione. Many protein-rich foods contain cysteine and methionine (the sulfur amino acids) and glycine. For example, chicken, turkey, pork, beef, fish, eggs, milk, beans, and nuts all provide these building blocks in varying amounts＊ () (). The MDPI nutrition review on dietary glutathione notes the best sources include meats and legumes: for instance, chicken breast has about 36 mg of GSH per 100 g (), and soybeans/rice have around 37 mg. Even some vegetables and fruits contain glutathione or precursors: spinach, asparagus, and avocado each have about 10–20 mg per 100 g (), while broccoli and citrus fruits offer modest amounts (). Note that cooking and processing reduce GSH in foods, so fresh or lightly cooked choices are better. There are also special dietary compounds that indirectly raise GSH. For example, garlic and onions contain water-soluble sulfur compounds (like S-allylcysteine) that help cells make more glutathione (). Vegetables in the cabbage family (broccoli, kale, Brussels sprouts) are rich in sulforaphane, which activates a gene regulator (Nrf2) that turns on the body’s GSH production enzymes (). Berries, tea, and foods with resveratrol or omega-3 fats can also boost antioxidant defenses by promoting GSH recycling (). Conversely, a strictly low-protein diet (such as some strict vegans or ancient fasting practices) may limit glutathione because it cuts glycine and cysteine intake (). Practical advice. Eating a protein-containing meal will help GSH. For example: Poultry, fish, eggs: high in methionine/cysteine. Legumes and beans: provide cysteine plus fiber and nutrients. Garlic/onions: use raw or lightly cooked for their sulfur compounds. Leafy greens & broccoli: not only give some glutathione but also activate its synthesis. Bone broth or gelatin: rich in glycine. Whole grains and nuts: contain smaller amounts but add variety. Over-supplementing protein is not needed, but ensure you get enough protein (especially when healing from surgery) to support glutathione and tissue repair. Adequate B-vitamins (B6, B12, folate) are also important to convert methionine into cysteine, completing the glutathione cycle. Overall, a balanced diet with a mix of these foods can modestly raise GSH levels without any side effects. Some people may notice gas or mild stomach upset from beans or cruciferous veggies, but such foods are generally safe. Glycemic Control and GI Tolerability When choosing a strategy, it’s helpful to compare how each affects blood sugar and digestion: Lowers Fasting Glucose or Insulin: GlyNAC has strong effects on insulin resistance (as seen above) (). NAC alone mostly lowers insulin demand in insulin-resistant states (). Glycine alone sharply reduces blood sugar spikes from a meal (). A protein-rich diet with vegetables tends to have a low glycemic load, improv Support the show

    14분
  4. Week 2 After Trabeculectomy: Transitioning to Light Chores and Remote Work

    6월 22일

    Week 2 After Trabeculectomy: Transitioning to Light Chores and Remote Work

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/week-2-after-trabeculectomy-transitioning-to-light-chores-and-remote-work Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Second Week After Trabeculectomy: Easing Into Daily Activities After trabeculectomy (glaucoma filtration surgery), the first week is usually very gentle – plenty of rest, limited movement, and protective measures (like an eye shield) as directed by your surgeon. By the second week, if your doctor gives the all-clear, you can begin to gradually resume light activities. For example, many patients feel well enough to do easy housework (like dusting, cooking, or folding laundry) and even return to light desk work or remote work around 1–2 weeks post-op (). (A health guide notes most patients can return to their normal routine by week 2 ().) Listen to your body: if your eye feels uncomfortable or tired, slow down or take a break. Don’t rush; your eye is still healing. Safe Chores and Work Light household tasks: Easy chores (such as making the bed, light laundry, tidying up) are usually okay after week 2. For example, one eye clinic advises that patients can “bend and do usual household tasks” and even gardening soon after surgery (). Make simple tasks easier: use a cordless vacuum or small hand vacuum for dusting, which reduces bending and lifting. A rolling laundry cart or tote can help move clothes without carrying heavy baskets. Remote work tips: If your job allows partial remote work, start with just short periods at a computer. Position your screen at eye level, sit in a well-lit room, and minimize overhead glare. Take frequent microbreaks: follow the 20-20-20 rule, looking at something about 20 feet away for 20 seconds every 20 minutes (). This helps relax your eye muscles and prevent strain. You might also use dictation tools or screen readers to reduce long periods of reading. Many phones and computers have built-in voice-to-text or text-to-speech features. For instance, smartphones often offer voice dictation and “screen reader” accessibility tools. These can help you work without staring at the screen for hours. Lifting, Bending, and Exercise Avoid heavy lifting: For at least 2–3 weeks, do not lift heavy objects. In many guidelines, “en evitar esfor\u00e7o f\u00edsico forte” and “no carrying weight above 5 kg (about 10 lbs)” for the first 2–3 weeks are recommended (). Think twice before lifting anything heavy: ask for help with groceries or laundry bags. Bend with your knees: When picking up objects, bend at your knees rather than bending over at the waist. Keeping your head above chest level helps avoid spikes in eye pressure. A Brazilian post-op guide specifically warns to be careful “ao abaixar a cabe\u00e7a al\u00e9m linha do ombro” – i.e. not to lower the head past shoulder level (). This is similar to general advice after eye procedures: don’t stoop forward too deeply. Instead, squat or kneel to reach lower items. Gradual exercise: Avoid strenuous exercise or heavy housework for the first two weeks () (). This means no running, aerobic workouts, or intense gym sessions. After two weeks, you can slowly ease back into gentle exercise (like walking). Always follow your surgeon’s guidance: if in doubt, double-check before attempting anything too energetic. Skip head-down positions: Activities like yoga poses that put the head below the heart (e.g. downward dog or forward bends) can sharply raise intraocular pressure. It’s safest to avoid inverted or head-lowered positions until you’re fully healed. Protecting Your Healing Eye Hand hygiene and drops: Infection prevention is vital. Always wash your hands with soap and water before touching your eyes or applying drops (). Your doctor will prescribe antibiotic and anti-inflammatory eye drops (and sometimes a steroid drop) to prevent infection and control inflammation () (). Use them exactly as directed. For example, GoodRx notes that after common eye surgery, patients use antibiotic and anti-inflammatory drops to “prevent complications such as… eye infection” (). Similarly, a trabeculectomy post-op guideline stresses that antibiotic and steroid drops are fundamental to a successful recovery (). Avoid touching or rubbing: Never rub or press on the operated eye for at least the first week (). Even after that, be gentle. If you need to clean around the eye, do so very carefully. One care sheet reminds patients to keep water, soap, shampoo and other products out of the eye, especially for the first week (). When showering, wash above the eyes with closed lids or use a gentle spray away from the face. Avoid swimming pools, hot tubs, or anything that might expose your eye to bacteria for at least a month (). No makeup or lotions: Do not wear eye makeup (mascara, eyeliner, eye shadow) for about 2 weeks after surgery (). Also, avoid applying perfumes or skincare creams near the eyes during this time. Keeping the eye area clean and free from potential irritants helps prevent infection. Sun and Light Protection Wear UV-blocking sunglasses: Your eye may be light-sensitive after surgery. Protect it outdoors with wraparound sunglasses that block 100% of UVA/UVB rays (). The American Academy of Ophthalmology recommends UV400 sunglasses – these block all harmful rays – for outdoor use (). In the first week especially, wear sunglasses any time you go outside (). This shields your eye from glaring light, wind, dust and pollen (which can burn or irritate a fresh surgical site). The Southwest Eye Institute notes that sunglasses “make [the light sensitivity] transition far more comfortable, and protect healing eyes from UV and debris” (). Use clean shields: Keep your sunglasses clean. A Brazilian clinic suggests washing post-op protective eyewear with soap and water, and putting them on by the arms (rather than touching the lenses) (). Clean, well-fitting sunglasses or a plastic shield (often provided by your doctor) can also be used indoors or at night to prevent accidental rubbing while sleeping. If an eye shield was given at night, continue wearing it for the first week or as instructed (). Reducing Eye Strain Even while recovering, digital screens are often necessary for work or leisure. To prevent digital eye strain, follow these tips: 20-20-20 breaks: Every 20 minutes, take a 20-second break and look at something about 20 feet away (). This simple “20-20-20 rule” is recommended by eye doctors to relax the eyes (). Setting a silent timer or using a break reminder app can help you remember. Blink often: Remind yourself to blink fully, especially if you feel dry. Blinking refreshes the tear film and keeps your eye lubricated. Optimize your screen: Use larger text and higher contrast on your computer or phone so you don’t have to squint. Position your device so you can sit upright, with the screen at or below eye level (this also helps keep your neck relaxed). Reduce glare by using curtains or an anti-glare filter on the screen. Voice/personal assistants: Take advantage of speech-to-text or voice assistant features. For example, you can dictate emails or documents instead of typing and reading long passages. On smartphones, voice commands (like Siri or Google Assistant) can control basic functions hands-free. For extensive reading, consider text-to-speech apps or built-in screen readers. Scheduled microbreaks: Throughout your day, stand up, stretch, and rest your eyes for a minute or two. Simple neck rolls and gentle shoulder stretches help you relax and improve circulation (just avoid bending forward deeply while stretching). Conclusion By week two, many patients find they can cautiously increase activities while still taking precautions for their healing eye. The key is moderation and protection. Stick to light housework and taking short stints of remote work with frequent breaks () (). Continue to follow your surgeon’s instructions on drops and follow-up visits. Avoid lifting heavy items or intense workouts for at least two more weeks () (). Always protect your eye – from infection and from UV/debris – by keeping hands clean, using your medications, and wearing sunglasses outside () (). Your eye is healing, but with these gentle guidelines and simple aids (like a lightweight vacuum or using voice dictation to rest your eyes), many normal activities can resume. If anything feels off – such as increasing eye redness, pain, or vision changes – contact your doctor promptly. Otherwise, implementing these care tips should help you recover comfortably and safely. ... Continue reading at https://visualfieldtest.com/en/week-2-after-trabeculectomy-transitioning-to-light-chores-and-remote-work Support the show

    9분
  5. Days 5–7 After Trabeculectomy: Completing Week One With Safer Routines and Visual Comfort

    6월 20일

    Days 5–7 After Trabeculectomy: Completing Week One With Safer Routines and Visual Comfort

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/days-5-7-after-trabeculectomy-completing-week-one-with-safer-routines-and-visual-comfort Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Days 5–7 After Trabeculectomy: Completing Week One With Safer Routines and Visual Comfort After a trabeculectomy (glaucoma surgery), the first week is all about gentle healing and carefully reintroducing normal tasks. By days 5–7, you’ll likely feel a bit better, but your eye is still fragile. It’s common to notice light sensitivity (you may find bright lights or sunlight harsh) and vision that goes from clear to fine to a bit blurry on different days. For example, one surgical recovery guide notes that “by the end of the first week, many patients notice gradual improvement in comfort and mild improvement in clarity, although vision may still fluctuate.” This means you might see better some hours, then foggy the next — this is normal as your eye pressure settles and the new drainage bleb (tiny fluid pocket) matures. You may also find your eye feels scratchy, watery, or a bit sore, especially from the tiny stitches (sutures). Malik and colleagues explain that the eye often feels like there’s a foreign body or scratchy sensation from stitches, but this usually causes only mild discomfort (). Your eye could be red and irritated, and it might water more than usual (). A common analogy surgeons use is that you’ve got a small, healing wound on your eye – some swelling and watering is expected. It’s important not to rub or press on the eye during this time, as even small jostles can disturb the healing. Medications continue in week one. Keep taking all prescribed eye drops exactly as directed – usually an antibiotic to prevent infection and a steroid to control inflammation. These are often used for several weeks and then gradually tapered (). If you have scheduled acetaminophen (Tylenol) or other mild pain medicine, you can use it for any soreness; Ibuprofen-type pain relievers are typically not needed. Most people find that over-the-counter acetaminophen is enough for the mild ache described by Greenwich Ophthalmology’s timeline (). By the end of day 7, you should be sleeping and waking with slightly less irritation than Midweek. Managing Comfort and Vision Even as the eye feels better, vision clarity can still change daily. It’s usual to have some blur or variability. The surgeon at Oracle Eye Physicians explains that in these first weeks “vision is quite variable,” sometimes almost normal and other times blurry, but it should slowly return to your previous level over several weeks (). In practice, this means some morning you wake up seeing very clearly, and another day everything might look fuzzy or cloudy. Don’t panic — this is part of normal recovery as your eye pressure stabilizes. To cope with light sensitivity and variable vision: Use sunglasses indoors and out. If lights feel bright or driving at dusk bothers you, wearing sunglasses can shield your eye from glare (). Many doctors recommend sunglasses especially when you’re outside or in brightly lit rooms. Minimize eye strain. In general, rest your eyes as much as possible. During days 1–3 most doctors advise resting your eyes and avoiding any extended reading or screen time (). By days 5–7 you can try short periods of reading or looking at a screen, but keep them brief and break often. Stay on your drop schedule. Continuing inflammation control is key for comfort. Every drop of steroid or antibiotic is important to prevent swelling and discomfort. Safer Screen Time and Reducing Eye Strain You might be wondering when you can get back to screens (phone, computer, TV). By days 5–7, light use is generally okay, but it’s wise to follow ergonomic and eyestrain-reducing practices. The American Academy of Ophthalmology (AAO) and other experts offer simple tips to protect healing eyes from digital strain: Take frequent breaks. Use the “20-20-20” rule: every 20 minutes, look at something 20 feet away for at least 20 seconds (). This rest lets your eyes refocus and blink normally. Maintain good distance and posture. Sit upright at a desk or table with the screen about an arm’s length away (~25 inches). Position the screen so your gaze is slightly downward (the top of the display just below eye level) (). This reduces eye strain and neck tension. Adjust light and contrast. Make sure room lighting isn’t too dim or too bright compared to the screen. Increase your screen contrast so text stands out; as one guide notes, ensure your screen’s brightness roughly matches the room light (). Use matte screen protectors or anti-glare filters if you’re in a bright room. Use large, clear text. On computers or phones, bump up the font size. Experts recommend at least a 12-point (or larger), dark text on a light background for easier reading (). High-contrast visual themes (dark mode vs light mode, etc.) that suit your comfort can help reduce squinting () (). Blink often and lubricate. We tend to blink less when staring at screens, so remind yourself to blink or look away. Keep preservative-free artificial tears handy during the day. If your eye feels dry, apply drops as needed – the AAO explicitly suggests keeping drops at hand to “help lubricate your eyes when they feel dry” (). A small room humidifier or steam (like from your shower) can also ease dryness in winter or air-conditioned environments. Follow any specific instructions from your doctor about screen use. There’s no strict “safe hours per day” rule, but many surgeons advise not pushing it in the first week. Instead of marathon sessions, do short bursts (5–10 minutes) and rest frequently. Regarding blue light, don’t fret too much: researchers have found that special blue-light blocking glasses or filters don’t reduce digital eye strain more than neutral (clear) filters (). However, using a device’s “night mode” or blue-light reduction setting in the evening can help with sleep even if it doesn’t directly prevent strain. So, if it’s easier on your eyes or helps you settle at bedtime, go ahead and use the blue-light filter—but focus more on all the other healthy screen habits above. Activity Restrictions Your doctor gave you rules for a reason: protect that fresh surgical site! In days 5–7, the main restrictions usually remain in place from day one, unless told otherwise: No swimming or submerging your face. Avoid pools, hot tubs, lakes, or even face-down baths for at least 2–4 weeks (). Bacteria in water can cause infection in the healing eye. Showering is allowed (starting the day after surgery), but be careful to keep water, soap, shampoo and conditioner out of the eye (). You can wash your hair, but tilt your head back and/or use gentle water flow so nothing runs into the eye. Avoid dusty or dirty environments. Skip gardening, yard work, dusting, or home renovation for now. Dirt and dust can irritate the eye or introduce germs. Kaiser’s guide specifically says to avoid gardening and dust for 1–2 weeks (). If someone else can do the chores, let them – or wear protective goggles if absolutely needed (but generally best to wait until clear). No heavy lifting or straining. Lifting heavy objects, straining (including heavy housework), and even bending forward can sharply raise pressure in the head and eye. For the first 2 weeks (and often longer), avoid lifting more than about 5–10 pounds, and do not bend over at the waist. Instead, bend your knees and lift with your legs if you must pick something up (). One surgeon’s instructions say, “Strenuous activity, heavy lifting, and bending over should be avoided for the first one to two weeks.” (). This also means no weightlifting, no exercise that makes your face red (like running or aerobics), and even avoid straining on the toilet: ask your doctor about using a stool softener if needed () (). Follow medication timing and precautions. Keep your eye shield or patch on at night for at least the first week (as your doctor recommended) to prevent you from accidentally rubbing your eye in sleep (). During the day, wear your regular eyeglasses if you have them, and don’t try to wear contact lenses for many weeks. Kaiser notes that patients usually need to avoid contacts for about 8 weeks after a trabeculectomy (). In short, take it very easy. If it’s strenuous for the body, it’s strenuous for the eye. Use assistance for any chores that involve bending, lifting above waist, or splashing of any kind. To make life easier, consider using prepared meals or meal kits. These ready-made or easy-prep dinner kits can cut down on time spent chopping, lifting pots, and bending over counters – lowering the strain on your eye during this vulnerable week. Follow-Up Care and Next Steps Your doctor will schedule follow-up visits to monitor healing. It’s typical to have an appointment the day after surgery, and then several visits in the first few weeks () (). Day 1 post-op: Wear your protective shield at night and have someone drive you in. At this visit, the surgeon will usually remove the patch, check your vision and pressure, and look at the new bleb (the little fluid-filled reservoir) (). They will give you any new drop instructions and be explicit about what activities to avoid. Week 1: You’ll likely return in about a week (day 5–7). The doctor will check how the bleb is working and may adjust sutures if needed. Kaiser Permanente Support the show

    14분
  6. Days 3–4 After Trabeculectomy: Calming Inflammation While Staying Mobile

    6월 19일

    Days 3–4 After Trabeculectomy: Calming Inflammation While Staying Mobile

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/days-3-4-after-trabeculectomy-calming-inflammation-while-staying-mobile Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Days 3–4 After Trabeculectomy: Calming Inflammation While Staying Mobile If you had trabeculectomy surgery for glaucoma, your body is now in the early healing phase. It’s common at this stage (around days 3–4) for your eye to be red and swollen and for your sight to be blurry or fluctuating. Don’t worry – this is usually normal. The eye’s natural response to surgery is to be a bit inflamed at first. Most patients still have some redness or a “bloodshot” look in the operated eye during the first 1–4 weeks (). Likewise, your vision may still be far from perfect. You might notice it going in and out of sharpness: one moment your sight seems nearly normal, the next it feels quite hazy () (). This happens as pressure and fluid levels in the eye adjust and as stitches and swelling settle. Typically, blurred vision after trabeculectomy starts to improve after a week or two and returns to its best over a few months () (). In short, expect ups and downs in comfort and clarity at this stage, but no need to be alarmed if each day brings a little better vision. To help calm inflammation, your surgeon will have prescribed anti-inflammatory eye drops. These are usually steroid drops (for example, dexamethasone) and sometimes a non-steroidal anti-inflammatory acetate drop. In the first days after surgery, you’ll likely use them very frequently. For instance, one clinic’s protocol is to put in steroid drops every 1–2 hours while awake for the first few days, then gradually taper to a few times per day over the next weeks (). Another guide recommends continuing steroid drops every 2 hours during the day for about the first month, then slowly reducing the dose over 2–3 months (). It’s vital to follow your exact drop schedule. These anti-inflammatory drops (and the prescribed antibiotic drops) prevent infection and control swelling so your new drainage “bleb” can form properly () (). Don’t stop them early, and try not to miss doses. Always wash your hands before touching your eye, and close your eye for a minute after each drop so it can soak in. Activity and Precautions While you should avoid strenuous activity or stress on the eye, it’s also good to stay as mobile as you safely can. In general, doctors advise moderate rest but not complete bed rest. You can sit up, walk around indoors, and do light tasks. For the first 1–2 weeks, however, be sure to avoid heavy lifting, bending, or anything strenuous. For example, avoid lifting anything heavier than about 10 pounds (a small bag of groceries) and refrain from jogging, weight-lifting, or intense housework () (). Bending forward (for example, to tie shoes or pick something from the floor) can temporarily raise eye pressure. To protect the eye, plan tasks ahead to minimize stooping. A reacher grabber tool can help pick up items without bending. If climbing a ladder or heavy lifting is part of a chore, wait until your doctor says it’s safe. According to guidelines, even ordinary housekeeping (dusting, vacuuming, cleaning) should be gentle or postponed for about a week or two (). These chores can stir up dust or require bending/straining, which could irritate the healing eye. Avoid dusty or smoky environments whenever possible. Airborne particles or smoke can irritate your eye’s surface or introduce germs. Health systems often advise using indoors air filters or masks if you must be in dusty areas. Also, don’t rub or press on the eye – even if it feels irritated, keep that reflex in check. Wear the prescribed eye shield at night (typically one week, or as directed) to prevent accidental rubbing while asleep (). If your eyes feel light-sensitive outdoors, use UV-blocking sunglasses or wraparound shades (preferably with side shields) to protect against wind, dust, and bright light () (). One often-overlooked step in recovery is preventing constipation. Straining on the toilet can significantly raise eye pressure, which you want to avoid while the eye heals (). Therefore, your doctor may recommend a high-fiber diet or a gentle stool softener. Keep your bowels easy-moving – for instance, consider fiber supplements or stool softener tablets each evening (but only if your doctor okays it) (). Drinking plenty of water also helps with this and supports healing overall. There are many mobile apps today to remind you to drink water regularly, which can be a handy tool during recovery. Warning Signs – When to Call Your Doctor While some redness and discomfort are expected, watch closely for any worsening symptoms. Alert your doctor immediately if you experience any of the following: Severe or increasing eye pain that doesn’t get better with your usual pain relievers. Some soreness is normal, but sharp or throbbing pain is not (). A pus-like (purulent) discharge: thick yellow or green fluid coming from the eye is a red flag for infection (). A rapid drop or change in vision beyond mild blurring. If your vision suddenly gets much worse or you see a new dark or “shadow” area, call urgently (). Halos or colored rings around lights, especially accompanied by a headache or eye pain. These can signal a dangerous rise in eye pressure (similar to an acute glaucoma attack) (). (If your eye also becomes very red or brownish, that is another warning sign.) Worsening redness or swelling that doesn’t start to improve after a few days. Persistent redness or a swollen eyelid might mean inflammation is not subsiding as expected (). Any signs of infection elsewhere: fever, chills, or feeling generally unwell. If you see any of these, it’s better to err on the side of caution. Many hospitals stress that infection and severe pressure problems can cause permanent vision loss if not treated promptly () (). Don’t wait – contact your eye surgeon or go to the emergency room if needed. Practical Tips for Comfort and Safety Eye shield or patch: Continue using an eye shield at night as directed. This prevents accidental rubbing. Some people keep a plastic shield taped over the eye at bedtime for the first few nights (). Pain management: Take over-the-counter acetaminophen (Tylenol) every 4–6 hours as needed for discomfort. Do not use aspirin or ibuprofen unless your doctor approves, since these can increase bleeding risk (). Stool softeners/fiber: As noted, take any recommended fiber supplement or stool softener to make bowel movements easy (). Hydration: Sip water throughout the day. Good hydration helps your body heal and keeps the eye moist. Setting reminders on your phone can help you drink regularly. Light activity: Short walks around the house are fine. You can read, watch TV, or do hobbies like knitting or light crafts – anything that doesn’t involve bending or heavy effort. Use caution if walking outside; wear your sunglasses. Reacher/grabber tools: Use a reaching tool for tasks that would otherwise require bending, like picking things off the floor or reaching low shelves. This avoids pressure spikes from bending. Eyedrop organizer or app: If you have a complicated drop schedule, use a pillbox-style drop organizer or a phone app (there are “eye drop reminder” apps) to track each dose. This helps ensure you don’t miss anti-inflammatory or antibiotic drops. Above all, follow your surgeon’s instructions. Attend all follow-up visits (often scheduled weekly at first) so the doctor can monitor your bleb (the filtering area) and eye pressure. They may adjust stitches or medications in the early weeks to keep your pressure in the safe range. Recovery can be a bit unpredictable, but staying on top of drops and restrictions will help everything settle down. Conclusion By days 3–4 after trabeculectomy, you should be gently resuming normal life while still taking good care of your eye. Some redness, mild soreness, and blurred vision are normal. Use your anti-inflammatory eye drops exactly as prescribed to calm swelling () (). Keep strenuous activities on hold, protect the eye from irritants (dust, smoke, bumps), and prevent any straining in daily tasks. Be mindful of any warning signs (worsening pain, pus, halos) and report them immediately. With these precautions – along with simple aids like stool softeners, sunglasses, hydration reminders, and reachers – you can support a smooth recovery and protect your vision. Always ask your surgeon or nurse if you have questions; good communication and safe habits are key to getting back to full strength. ... Continue reading at https://visualfieldtest.com/en/days-3-4-after-trabeculectomy-calming-inflammation-while-staying-mobile Support the show

    9분
  7. How Does the PreserFlo MicroShunt Stack Up Against Trabeculectomy and Other Drainage Devices?

    6월 16일

    How Does the PreserFlo MicroShunt Stack Up Against Trabeculectomy and Other Drainage Devices?

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/how-does-the-preserflo-microshunt-stack-up-against-trabeculectomy-and-other-drainage-devices Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Introduction For people with open-angle glaucoma, surgical options aim to lower intraocular pressure (IOP) by creating a new drainage pathway for eye fluid (aqueous humor). The traditional gold-standard surgery is trabeculectomy, a technique that creates a small hole under a scleral flap, forming a filtering bleb under the conjunctiva. In recent years, newer implants have emerged. These include tube shunts (Ahmed, Baerveldt, Molteno implants) that channel fluid from the front of the eye to a plate under the conjunctiva, and minimally-invasive glaucoma surgeries (MIGS) such as the XEN Gel Stent and PreserFlo MicroShunt. The PreserFlo MicroShunt (formerly InnFocus MicroShunt) is a small, ab-externally implanted glaucoma device made of a soft polymer (poly(styrene-block-isobutylene-block-styrene), or SIBS). It drains fluid from the anterior chamber into a posterior subconjunctival bleb. This device is meant to be less invasive than trabeculectomy yet more effective than purely bleb-less MIGS. In this review, we compare PreserFlo to trabeculectomy and other drainage devices (Ahmed valve, Baerveldt and Molteno implants, XEN stent) in terms of how they work, clinical effectiveness, safety, practical use, and current access/cost issues. We use evidence from published trials and registries. When we report results, we note sample sizes and study years. If data are limited or mixed, we say so. Key findings are summarized in the concluding table. Background and Mechanism PreserFlo MicroShunt: The PreserFlo device is an 8.5 mm long tube with a 350 µm outer diameter and a very narrow 70 µm inner lumen (). It is made of SIBS, a biocompatible polymer that resists biodegradation (). The surgeon opens a small conjunctival/Tenon’s flap (much like for trabeculectomy) and uses mitomycin-C (an antifibrotic) under the flap. The MicroShunt is inserted ab externo: a tiny pocket is made in the sclera to accept the device fins, and a tunnel is made into the anterior chamber. The proximal tip sits inside the eye (just anterior to the iris) and the distal end drains fluid beneath the conjunctiva (see image below). Because the lumen is very small, it provides some flow resistance to help prevent severe postoperative hypotony (very low pressure). () Figure: The PreserFlo MicroShunt (red arrow) shunts aqueous humor from the anterior chamber (right) to a bleb under the conjunctiva (left) (). Trabeculectomy: In trabeculectomy, the surgeon creates a scleral flap and manually makes an opening under it (sometimes removing a small piece of iris) to connect the anterior chamber to the subconjunctival space. This creates a bleb. Mitomycin-C is often applied. Trabeculectomy is highly effective at lowering IOP, but it is invasive: it requires extensive dissection, sutures, and careful postoperative management. Tube Shunts (Ahmed, Baerveldt, Molteno): These are aqueous drainage implants. A silicone tube is inserted through the sclera into the anterior chamber. The tube drains fluid to a plate placed under the conjunctiva. The Ahmed Glaucoma Valve (AGV) includes a one-way valve designed to prevent early hypotony. The Baerveldt implant (typically 350 mm² plate) and Molteno implant (typically 275–350 mm²) are non-valved; surgeons ligate or occlude the tube temporarily to prevent immediate overdrainage. In general, valved shunts (Ahmed) cause less early hypotony but may end up at slightly higher pressures, while large non-valved shunts (Baerveldt, Molteno) can achieve lower long-term IOP but risk early overdrainage if not carefully tied off. XEN Gel Stent: The XEN 45 is a soft, gelatin-based 6 mm tube with a 45 µm lumen. It is implanted ab interno (from inside the eye) through a small corneal incision. It also drains to a subconjunctival bleb. No scleral dissection or removable flap is needed – only a gentle subconjunctival elevation of conjunctiva is done and mitomycin-C is often injected under the conjunctiva. Because the XEN lumen is slightly larger than the aqueous outflow resistance of normal trabecular pathways, it provides a controlled flow (and 45 µm lumen is internally limiting flow to avoid hypotony). However, like PreserFlo, it relies on bleb formation and often requires postoperative management (needling) of the bleb. MIGS vs Traditional Spectrum: Surgical options range from classic filtration surgery (trabeculectomy/tubes) at one end to ab interno MIGS at the other. MIGS are generally defined as procedures with an ab interno approach, minimal tissue trauma, faster recovery, and a good safety profile (). Examples of ab interno MIGS that do not form a bleb include stents in Schlemm’s canal (iStent, Hydrus) or suprachoroidal devices. PreserFlo, XEN, and older shunts are unique because they do create a bleb. These “bleb-forming MIGS” are sometimes considered intermediate: they are less invasive than trabeculectomy (especially XEN, which is minimally dissected) but not as simple as trabecular bypass stents. In practice, PreserFlo and XEN are often lumped into the MIGS group (despite ab externo steps in PreserFlo’s case) because they aim to reduce invasiveness and management burden. Efficacy Outcomes IOP Reduction and Success Rates: Clinical studies show that PreserFlo consistently reduces IOP into the mid-teens. In Baker et al. (2021), a large randomized trial of 527 eyes (395 PreserFlo, 132 trab) reported one-year IOP falls from 21.1±4.9 to 14.3±4.3 mmHg (–29% from baseline) after MicroShunt, versus 21.1±5.0 to 11.1±4.3 mmHg (–45%) after trabeculectomy (). Corresponding mean glaucoma medications dropped from 3.1 to 0.6 in the PreserFlo group and 3.0 to 0.3 in the trab group (). By Baker’s success criteria (≥20% IOP reduction without more meds), 53.9% of PreserFlo eyes and 72.7% of trabeculectomy eyes “succeeded” at 1 year (P20% IOP reduction without medications (). Mean IOP at 1 year was 12.9±3.4 mmHg (PreserFlo) and 11.4±4.5 mmHg (trab) (). Medications fell from ~2.5 to 0.4 in the PreserFlo group and to 0 in the trab group (). These results again favor trabeculectomy for lower final IOP, though both groups reached low teens pressures. Other PreserFlo series report similar IOP control. For example, Beckers et al. (2022) studied 81 eyes with PreserFlo at 2 years. Mean IOP fell from 21.7±3.4 mmHg at baseline to 14.5±4.6 mmHg at 1 year and 14.1±3.2 mmHg at 2 years (P0.0001) (). Overall success (with or without meds) was 74.1% at 1 year (). Medications dropped from 2.1 to 0.5 (mean) by 2 years, with 73.8% of patients medication-free (). In their study, higher mitomycin-C (0.4 mg/ml) trended toward better pressure and med reduction than 0.2 mg/ml (). PreserFlo vs XEN: Available data suggest similar efficacy between these two bleb-based MIGS. In a 2-year comparative series, Scheres et al. (2022) found that mean IOP dropped from 20.1 to 12.1 mmHg (PreserFlo) and from 19.2 to 13.8 mmHg (XEN) at 2 years (p=0.19) (). The probability of “qualified success” (achieving target IOP with or without meds) was 79% for PreserFlo vs 73% for XEN at 24 months (). Both groups had substantial medication reduction. Thus, in this series the two devices gave nearly equivalent pressure outcomes. PreserFlo vs Tube Shunts (Ahmed/Baerveldt): There are no head-to-head trials of PreserFlo versus tube implants. For context, device trials provide a ballpark: The Ahmed vs Baerveldt ABC Study showed at 1 year mean IOP ~15.4 mmHg with Ahmed vs 13.2 mmHg with Baerveldt when starting from 31 mmHg (). Both used adjunctive medications. These results imply that large plate tube shunts can achieve very low pressures (down to ~13 mmHg) often slightly lower than PreserFlo’s typical outcome (low teens). On the other hand, tubes carry more serious surgery for difficult cases. In practice, PreserFlo tends to be used in mild-to-moderate glaucoma; Ahmed/Baerveldt in refractory or severe cases. Longer-Term Durability: Prestigious controlled data (like Baker et al.) reported only 1-year results so far. Longer follow-up is still needed. In the Beckers 2-year series, PreserFlo pressure control was sustained at ~14 mmHg through 2 years (). Fili’s study was only 1 year. The Scheres XEN vs PreserFlo study also had 2-year data (). Notably, Baker’s trial is designed for 2 years (NCT01881425), and longer-term data should clarify durability of the MicroShunt vs trabecular outcomes. Safety and Complications Hypotony (Low IOP): Shunt surgeries often have early postoperative hypotony. In Baker et al., transient IOP ≤5 mmHg occurred in 28.9% of PreserFlo eyes versus 49.6% of trabeculectomy eyes (P0.01) (). Thus, while PreserFlo had less frequent shallow pressure than trab, more than a quarter of eyes did have an IOP hump to ≤5 mmHg after MicroShunt. Serious hypotony-related complications (maculopathy or required reformation) we Support the show

    27분
  8. Lowering Eye Pressure: The Lumigan vs Roclanda Showdown

    6월 15일

    Lowering Eye Pressure: The Lumigan vs Roclanda Showdown

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/lowering-eye-pressure-the-lumigan-vs-roclanda-showdown Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Lowering Eye Pressure: The Lumigan vs Roclanda Showdown Open-angle glaucoma and ocular hypertension are conditions where intraocular pressure (IOP) is higher than normal, threatening vision. Eye drops that reduce IOP are the first-line defense. In this “showdown,” we compare Lumigan (brand of bimatoprost) and Roclanda (called Rocklatan in the US, a fixed-dose combo of latanoprost + netarsudil) – explaining how each works, how well it lowers pressure, side effects, dosing, cost, and which patients might benefit most. Mechanism of Action The two drops work differently. Lumigan (bimatoprost) is a prostaglandin analogue. Prostaglandin analogues act mainly by increasing the drainage of fluid out of the eye (especially via the uveoscleral outflow pathway). Bimatoprost is converted in the eye to a form that boosts outflow of aqueous humor, reducing pressure. For example, laboratory studies show bimatoprost lowers resistance in the trabecular meshwork by about 26% (). Clinically, bimatoprost and other prostaglandins (like latanoprost) share this main effect: more fluid drain leads to lower IOP () (). Roclanda (latanoprost + netarsudil) combines two actions. The latanoprost part is another prostaglandin, working like bimatoprost to improve outflow. On top of that, netarsudil is a Rho kinase (ROCK) inhibitor – a different class. Netarsudil’s unique action is to relax the eye’s conventional drainage meshwork (trabecular meshwork) and lower the pressure needed to push fluid out. It also has secondary effects: it can reduce pressure in the episcleral veins and even slightly reduce fluid production (). In short, while both drugs share the prostaglandin mechanism (increasing uveoscleral drainage ()), netarsudil adds a tug at the trabecular outflow route and venous side of things (). Efficacy Clinical trials show both Lumigan and the netarsudil/latanoprost combo can dramatically lower IOP, but the combo generally drops pressure further than latanoprost alone (and thus more than a single prostaglandin alone). Lumigan monotherapy typically reduces IOP by a large percentage. In trials of bimatoprost 0.03%, average drops of about 6–8 mmHg (roughly 25–35%) from baseline were seen (). For example, one analysis noted an average reduction around 7.7 mmHg. This means from a starting IOP in the mid-20s, many patients on Lumigan drop into the high teens. In fact, bimatoprost has consistently shown strong pressure-lowering: multiple studies and meta-analyses found it often lowers IOP slightly more than other prostaglandins like latanoprost (). For Roclanda/Rocklatan (netarsudil+latanoprost), phase-3 trials (the MERCURY studies) found even bigger drops compared to each drug alone. In those trials, adding netarsudil to latanoprost produced an extra 1.5–3 mmHg reduction in IOP beyond latanoprost alone (). In concrete terms, patients on the combination averaged IOPs around 15–16 mmHg at follow-up, compared to about 17–18 mmHg on latanoprost alone () (). Notably, at 3 months one study reported 42% of patients on the combo hit a mean pressure ≤15 mmHg, while only about 16–18% did so on latanoprost or netarsudil alone (). In pooled analyses, Roclanda patients had mean daytime IOP ~15–16 mmHg versus ~17–18 mmHg on latanoprost alone (). There are no direct head-to-head trials comparing Lumigan vs the netarsudil/latanoprost combo. (The recent MERCURY-3 trial compared the combo to bimatoprost/timolol rather than bimatoprost alone.) Thus we rely on separate data: prostaglandin drops like Lumigan give a strong single-agent effect, while the fixed combo can add on extra pressure reduction for those needing it. The combined drug is designed for patients not at target on a prostaglandin alone (). Side Effects and Tolerability Side effects of these drops are mostly well-known ocular reactions. Prostaglandin analogues (Lumigan’s bimatoprost and Roclanda’s latanoprost) commonly cause mild eye redness (conjunctival hyperemia), longer or thicker eyelashes, and gradual darkening of the iris color and surrounding skin () (). These changes come from the drug’s pharmacology – for example, Lumigan’s prescribing information notes pigmentation changes (iris, eyelid, lashes) and eyelash growth (). In practice, redness on Lumigan 0.01% affects about 30% of patients (); a higher 0.03% dose had more. Eyelash growth and iris darkening are not dangerous and can even be cosmetically welcome (they gave rise to Latisse eyelash formulation). However, the pigmentation changes tend to be permanent, and some patients dislike puffiness or deepening of the eye folds (“sunken eyes”) seen with prostaglandins. Overall, prostaglandin side effects are usually mild-to-moderate, but they lead many patients to notice their eyes look a bit different () (). Netarsudil, by contrast, has a distinctive side-effect profile. The most common issue is also redness – in fact, even higher than with prostaglandins. Clinical data report redness in over 50% of netarsudil-treated eyes () (). Netarsudil can also cause conjunctival hemorrhages (tiny red blood spots on the white of the eye) and corneal verticillata (whorl-like deposits on the cornea) in up to 10–20% of patients () (). For example, Rhopressa’s label notes ~53% hyperemia and about 20% cornea deposits or hemmorhages (). In Rocklatan trials, about 59% of combo patients had some hyperemia, and 11% had conjunctival bleeding and 15% had corneal deposits () (). Latanoprost’s own side effects (modest pigment/lash changes) can add to this but are relatively minor compared to the big difference in redness between netarsudil vs prostaglandin. In summary, Lumigan’s typical adverse effects: Eye redness (hyperemia) – very common (~31% on 0.01% ()). Eyelash and eyelid changes (growth, darkening) and possible eyelid fat loss () (). Iris color darkening (permanent) (). Roclanda’s common adverse effects (netarsudil + latanoprost): Hyperemia/redness – very common (~54–59% in trials) () (). Subconjunctival hemorrhage (small eye bleeds) – ~11% (). Corneal verticillata (deposits) – ~15% (). Eyelash or pigmentation changes (from the latanoprost) – generally milder than with bimatoprost. These side effects affect tolerability. In practice, up to ~40–45% of patients on a prostaglandin drop report some adverse event (), and redness is often the main complaint. The higher redness rate with netarsudil combinations can be uncomfortable – many patients describe mild stinging or a “bloodshot” eye that typically fades over time () (). Such effects do influence real-world use: patients bothered by redness or irritation may skip doses or switch drugs. (Interestingly, in the netarsudil vs latanoprost studies, some reported the red-eye of netarsudil tended to decrease after a month of nightly dosing.) Both drugs are usually given at bedtime in part to minimize noticing these effects during waking hours. Dosing and Convenience Both Lumigan and Roclanda are simple once-daily drops (usually one drop in the affected eye(s) each evening) () (). Lumigan 0.01–0.03% is instilled nightly, as is Rocklatan (netarsudil 0.02%/latanoprost 0.005%) () (). So neither requires multiple doses per day. A convenience point: Roclanda provides two active ingredients in one bottle. If a patient needs both a prostaglandin and netarsudil, using the fixed combo means only one dropper instead of two separate bottles. (For example, someone already on latanoprost who adds netarsudil could use Rocklatan and simplify their regimen.) By contrast, if a patient on Lumigan needs extra therapy, they would typically add a second bottle (another drug). The single-bottle combination can improve adherence for some patients by reducing the number of separate medications to juggle. Cost, Availability, and Approval Lumigan (bimatoprost) is a well-established medication. In the US it was originally approved in 2001 () (as 0.03%, and later 0.01%) and has parent-patent expiration spun off generics. Generic versions of bimatoprost 0.01% were approved around 2025 (). In practice, generic bimatoprost drops are now widely available, making this therapy relatively inexpensive with insurance or discount programs. (By contrast, the brand Lumigan without insurance can cost hundreds of dollars for a bottle, though coupons often reduce this.) Roclanda (latanoprost/netarsudil) is newer. The European Medicines Agency (EMA) gave approval in January 2021 (); it is marketed in the US as Rocklatan (FDA approval 2019). As a brand-name combination, it is pricier. There are currently no generic versions of the netarsudil/latanoprost combo; netarsudil itself is proprietary. Without insurance, Rocklatan’s cost is several hundred dollars for a month’s supply. Many insurance plans require patients to try simpler therapy first (for example, requiring failure of a prostaglandin drop before covering the combo). Regional differences apply: in Europe, Roclanda would be covered by national health systems similarly to other second-line glaucoma meds. Ideal Patient Profiles Lumigan (bimatoprost monotherapy) is often used as a first-choice eye drop for open-angle glaucoma or ocular hypertension () because it’s very effective and simple. It suits a patient whose target IOP is modes Support the show

    12분
모두 보기(202개)

소개

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

정보

좋아할 만한 다른 항목